Clinical trials: Biologic Markers
Solid Tumour
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
This is a multi-center, open-label Phase 0 Master Protocol in Australia designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumour microenvironment (TME) when administered intratumourally in…
- Trial name
- NCT04891718
- Testing
- MVC-101, Nivolumab, MVC-101 + Nivolumab
- Where
- 3 sites in Australia
- Sponsor
- Presage Biosciences
Neoplasm
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Continuous dosing of BAY73-4506 in patients with advanced cancer
- Trial name
- NCT01117623
- Testing
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Bayer
LRTI, UTI
Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections
This is an observational prospective study of an in-vitro diagnostic (IVD) assay planned to enroll 632 subjects. The study will be conducted in two stages: Stage A is aimed at identifying individual biomarkers and constructing a…
- Conditions
- LRTI, UTI, Gastroenteritis, Systemic Infections/Bacteremia/Meningitis
- Trial name
- CURIOSITY (NCT01917461)
- Where
- 2 sites in Israel
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Heart Failure
Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator
Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.
- Trial name
- ACAB (NCT04292405)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zoll Medical Corporation
Fibromyalgia (FM)
EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its…
- Trial name
- FM-TDCS-PREDIC (NCT07583056)
- Testing
- High-dose home-tDCS M1, Conventional home-tDCS, High-dose home-tDCS DLPFC
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Ionclinics & Deionic SL
Morquio Syndrome, Accumulation of Mucopolysaccharides
Biomarker for Morquio Disease (BioMorquio)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma
- Conditions
- Morquio Syndrome, Accumulation of Mucopolysaccharides, Morquio Syndrome A, Morquio B Disease
- Trial name
- BioMorquio (NCT01457456)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Colorectal Cancer, Advanced Colorectal Neoplasm
A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer
The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® CRC test for detecting CRC, using colonoscopy as the reference method.
- Conditions
- Colorectal Cancer, Advanced Colorectal Neoplasm, Advanced Adenomas, Non-neoplastic Polyps
- Trial name
- NCT05255588
- Testing
- EarlyTect® CRC test
- Where
- South Korea
- Volunteers
- 2,358 people
- Sponsor
- Genomictree, Inc.
Blood Self-Collection for Clinical Diagnostic Assessments
Evaluation of Tasso+ Blood Self-Collection for Clinical Diagnostic Assessment of Various Biomarkers
This study aims to assess the effectiveness and reliability of the Tasso+ capillary blood self-collection device in the clinical diagnostic assessment of various biomarkers.
- Trial name
- NCT05852925
- Testing
- Traditional Venipuncture, Tasso+
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- American Research Labs
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Inflammation and Fibrosis, Diabetes
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability, and effects on biomarkers of PBI-4050 in subjects with Alström syndrome for a treatment duration of 24 weeks.
- Trial name
- NCT02739217
- Testing
- PBI-4050
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Liminal BioSciences Ltd.
Healthy Volunteer, Autistic Disorder, Asperger's Syndrome
A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome
This multi-center, non-drug study will explore the relationship between exploratory biomarkers and functional dimensions in male adult individuals with Autistic Disorder or Asperger's Syndrome and healthy volunteer controls.
- Trial name
- NCT01669889
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Becker Muscular Dystrophy
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy
- Trial name
- MESA (NCT06066580)
- Testing
- Sevasemten
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 260 people
- Sponsor
- Edgewise Therapeutics, Inc.
Brain Injuries, Traumatic
Biomarkers of Traumatic Brain Injury With Tbit System
A prospective, multi-center, non-randomized, pivotal study to assess the safety and efficacy of the Tbit™ System to aid in patient evaluation, suspected of traumatic brain injury, as adjunct companion test to radiologic standard…
- Trial name
- NCT04107662
- Testing
- Tbit system
- Volunteers
- 740 people
- Sponsor
- BioDirection Inc
Infections, Sepsis
A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and…
- Conditions
- Infections, Sepsis, SIRS
- Trial name
- NCT05142813
- Testing
- Diagnostic Test: Blood specimen collection
- Volunteers
- 1,100 people
- Sponsor
- mProbe Inc.
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Disorders of Breast, Breast Lesions
Magseed Magnetic Marker Localization
The purpose of this post-marketing study is to provide prospective evidence that the Magseed and Sentimag® is effective for lesion localization in patients undergoing surgical excision of a breast lesion and to summarize measures…
- Trial name
- NCT03020888
- Testing
- Magseed and Sentimag
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Endomagnetics Inc
Glioblastoma, High-grade Glioma
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
- Trial name
- DUAL-CAR-NK-GB (NCT07480941)
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular…
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
- Trial name
- NCT06322641
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S